02096naa a2200217 a 450000100080000000500110000800800410001902200140006002400560007410000170013024501480014726000090029530000110030452014010031565300240171665300200174070000190176070000160177970000230179577300600181821486492024-12-10 2022 bl uuuu u00u1 u #d a0022-28607 ahttps://doi.org/10.1016/j.molstruc.2022.1342932DOI1 aDINIZ, L. F. aStructural aspects, solid-state properties, and solubility performance of pharmaceutical sertraline-based organic salts.h[electronic resource] c2022 a1 - 11 aSalt formation has been a traditional and successful strategy in modulating the biopharmaceutical physic-ochemical properties of the active pharmaceutical compound (API). Herein, we have prepared four saltsof Sertraline (Srt) with oxalic, fumaric, maleic and methanesulfonic acids to improve the thermal stabilityand solubility of the API. Anion-exchange reaction and solvent crystallizations have been undertaken toprepare salts of the Srt. These crystalline phases have been characterized by single-crystal and powder X-ray diffraction, Fourier transformed infrared spectroscopy, thermal analysis, and solubility measurements.From the single-crystal structures, we have observed that the carboxylate salts contain anion-water clus-ters that guide the formation of 1D-anion channels and structures that are then coupled to Srt+ cations.The mesylate salt (SrtH Mes), which is anhydrous, also has an alternating layered structure of cations andanions. SrtH Mes is the most thermally stable salt (m.p 194 ÂșC) and shows moderate solubility enhance-ments over the parent hydrochloride one, SrtH Cl. Given this profile, it represents an alternative for newdrug formulation, storage, and API purification. In this study, we show the application of crystal struc-ture assessments and their solid-state characterizations to guide and provide a selection of solid forms ascandidates for drug development. aCrystal engineering aPharmaceuticals1 aTENORIO, J. C.1 aRIBEIRO, C.1 aCARVALHO JR, P. S. tJournal of Molecular Structuregv. 1273, a134293, 2022.